Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report sales of $27.55 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Heron Therapeutics’ earnings. The highest sales estimate is $30.00 million and the lowest is $25.70 million. Heron Therapeutics posted sales of $11.57 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 138.1%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.
On average, analysts expect that Heron Therapeutics will report full year sales of $152.43 million for the current year, with estimates ranging from $137.50 million to $166.40 million. For the next fiscal year, analysts anticipate that the business will report sales of $331.88 million, with estimates ranging from $282.00 million to $386.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.17). The company had revenue of $28.84 million during the quarter, compared to the consensus estimate of $28.05 million. Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%.
NASDAQ HRTX traded up $0.70 during trading hours on Monday, reaching $24.40. 1,014,284 shares of the stock traded hands, compared to its average volume of 880,127. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.00 and a beta of 1.57. Heron Therapeutics has a 1 year low of $21.25 and a 1 year high of $42.90.
Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Heron Therapeutics by 24.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares during the last quarter. Jefferies Group LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $202,000. Verition Fund Management LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $208,000. Stephens Inc. AR purchased a new stake in shares of Heron Therapeutics in the 4th quarter valued at approximately $208,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $223,000.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.